BMC cancer · 2025
Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Du Juan, Ren Weiwei, Liu Wenjie, Zhou Yixuan, Li Yushan, Lai Qingyi, Liu Xiongying, Chen Tongsheng, Liu Wenjuan, Chen Zhuanming, Zhang Jinhe, Zhang Peipei, Yuan Jianwei
Аннотация
OBJECTIVE: To explore and compare the value of 131I-TFMP-Y4 and 131I-Caerin 1.1 in internal irradiation therapy for hepatocellular carcinoma.
METHODS: (1) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis revealed the inhibitory effects of Caerin 1.1 and TFMP-Y4 on Hepg2 and LO2 cell growth. (2) The chloramine-T method was used to prepare 131I-Caerin 1.1 and 131I-TFMP-Y4. (3) Uptake and elution assays revealed that Hepg2 cells bound and retained 131I-Caerin 1.1 and 131I-TFMP-Y4, and the inhibitory effects on Hepg2 cells were verified with cellular proliferation/toxicity assays. (4) A hormonal nude mouse model was established to study the in vivo therapeutic effects of the peptides alone, 131I-Caerin 1.1 and 131I-TFMP-Y4.
RESULTS: (1) Caerin 1.1 inhibited Hepg2 and LO2 cell proliferation in a concentration-dependent manner, and the half-maximal inhibitory concentrations (IC50) were 9.34 µg/mL and 22.16 µg/mL, respectively. Moreover, TFMP-Y4 did not inhibit these two cell lines. (2) The labeling rates of 131I-Caerin 1.1 and 131I-TFMP-Y4 were high and stable. Both could significantly reduce the activity of Hepg2 cells and inhibit tumor growth in vitro and in vivo.
CONCLUSION: 131I-Caerin 1.1 and 131I-TFMP-Y4 significantly inhibited the proliferation of Hepg2 cells in vitro and in vivo. In addition, 131I-TFMP-Y4 can reduce adverse reactions during treatment.
METHODS: (1) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis revealed the inhibitory effects of Caerin 1.1 and TFMP-Y4 on Hepg2 and LO2 cell growth. (2) The chloramine-T method was used to prepare 131I-Caerin 1.1 and 131I-TFMP-Y4. (3) Uptake and elution assays revealed that Hepg2 cells bound and retained 131I-Caerin 1.1 and 131I-TFMP-Y4, and the inhibitory effects on Hepg2 cells were verified with cellular proliferation/toxicity assays. (4) A hormonal nude mouse model was established to study the in vivo therapeutic effects of the peptides alone, 131I-Caerin 1.1 and 131I-TFMP-Y4.
RESULTS: (1) Caerin 1.1 inhibited Hepg2 and LO2 cell proliferation in a concentration-dependent manner, and the half-maximal inhibitory concentrations (IC50) were 9.34 µg/mL and 22.16 µg/mL, respectively. Moreover, TFMP-Y4 did not inhibit these two cell lines. (2) The labeling rates of 131I-Caerin 1.1 and 131I-TFMP-Y4 were high and stable. Both could significantly reduce the activity of Hepg2 cells and inhibit tumor growth in vitro and in vivo.
CONCLUSION: 131I-Caerin 1.1 and 131I-TFMP-Y4 significantly inhibited the proliferation of Hepg2 cells in vitro and in vivo. In addition, 131I-TFMP-Y4 can reduce adverse reactions during treatment.